Compass Therapeutics Provides Corporate Update

We continue to open clinical sites and enroll patients in COMPANION-002, the Phase 2/3 randomized study of CTX-009 in patients with advanced biliary tract cancer . Consistent with prior guidance, top...

Related Keywords

Boston ,Massachusetts ,United States ,Vered Bisker Leib ,Thomas Schuetz ,Danna Gifford ,Carl Gordon ,Compass Therapeutics Inc ,Exchange Commission ,Nasdaq ,Globenewswire Inc ,Development Pipeline Updates ,Compass President ,Compass Chief Executive Officer ,Compas Scientific Founder ,Chief Executive Officer ,Vice Chair ,Pipeline Updates ,Adaptive Simon Two Stage ,Annual Report ,Quarterly Report ,Communications Manager ,Markets ,